Trial
NCT04901988
Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
The Christie NHS Foundation Trust
Collaborators
University of Manchester; Manchester Academic Health Science Centre; University of Liverpool
Condition
Melanoma (Skin)
Intervention
Nivolumab 10 MG/ML
Why stopped
Closed earlier than expected due to the need for a redesign to reflect the recent change in standard of care guidelines. New design will include these treatments.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-27